Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/28/2003WO2003070252A1 Antipruritics
08/28/2003WO2003070251A1 Pharmaceutical combinations of cox-2 inhibitors and opiates
08/28/2003WO2003070250A1 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
08/28/2003WO2003070249A1 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
08/28/2003WO2003070248A1 Use of 4-(4-methylpiperazin-1-ylmethyl)-n[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]-benzamide for treating seminomas
08/28/2003WO2003070247A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
08/28/2003WO2003070246A1 Controlled synthesis of ziprasidone and compositions thereof
08/28/2003WO2003070245A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
08/28/2003WO2003070242A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
08/28/2003WO2003070240A1 New treatment for arthrits and edematous processes
08/28/2003WO2003070237A1 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
08/28/2003WO2003070236A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003WO2003070235A1 Medicinal compositions for inhibiting tryptase
08/28/2003WO2003070234A1 Alkylating agent combinations in the treatment of cancer
08/28/2003WO2003070233A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
08/28/2003WO2003070232A1 Anti-nausea and anti-vomiting activity of cannabidiol compounds
08/28/2003WO2003070231A1 Antibacterial compositions
08/28/2003WO2003070230A1 Use of agents that modulate pde11a activity
08/28/2003WO2003070229A2 Use of proteinase inhibitors in the treatment of autoimmune diseases
08/28/2003WO2003070228A1 Percutaneous absorption type plaster
08/28/2003WO2003070221A1 Chemosensitizing with liposomes containing oligonucleotides
08/28/2003WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
08/28/2003WO2003070219A1 Drug delivery system for the subconjunctival administration of fine grains
08/28/2003WO2003070218A1 Sustained-release ointment for topical administration
08/28/2003WO2003070217A1 Levothyroxine compositions and methods
08/28/2003WO2003070216A1 System for transvaginal drug delivery
08/28/2003WO2003070215A1 Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof
08/28/2003WO2003070204A2 Lipase inhibiting composition
08/28/2003WO2003070203A1 Orally administrable composition for the photoprotection of the skin
08/28/2003WO2003070193A2 RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070191A2 Tamper-resistant transdermal opioid delivery devices
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003070188A2 Method of treating trx mediated diseases
08/28/2003WO2003070184A2 Sodium channel blockers
08/28/2003WO2003070182A2 Sodium channel blockers
08/28/2003WO2003070181A2 Compositions and methods for preservation of food
08/28/2003WO2003070180A2 Compositions and methods for delivery of skin cosmeceuticals
08/28/2003WO2003070179A2 Phosphonate-phosphate and diphosphonate apolipoprotein e modulators
08/28/2003WO2003070177A2 Use of melatonin analogues for induction of general anesthesia
08/28/2003WO2003070175A2 Use of opioid compound to treat a neurologic or neurogenic disorder
08/28/2003WO2003070171A2 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
08/28/2003WO2003070169A2 Aminodiphosphonate apolipoprotein e modulators
08/28/2003WO2003070168A2 Method of treating inflammation and inflammation-related pain
08/28/2003WO2003070167A2 Therapeutic and prophylactic treatment of aging and disorders of aging in humans
08/28/2003WO2003070166A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003WO2003070163A2 Prostacyclin derivatives for treating cancer
08/28/2003WO2003070159A2 Novel coumarin and chromene compounds and methods of treating or preventing viral infections
08/28/2003WO2003070158A2 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
08/28/2003WO2003070157A2 Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
08/28/2003WO2003070156A2 Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
08/28/2003WO2003070155A2 Orally administrable pharmaceutical formulation
08/28/2003WO2003070153A2 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
08/28/2003WO2003070023A1 Amino acid powder and process for producing the same
08/28/2003WO2003070019A1 Pet food composition for skin photoprotection
08/28/2003WO2003069998A1 Stable compositions comprising tezacitabine
08/28/2003WO2003069993A1 Antimicrobial therapeutic compositions and methods of use
08/28/2003WO2003059397A3 Labeling targeting agents with gallium-68 and gallium-67
08/28/2003WO2003055559A8 Dialkyl-substituted acetic acid and glyceric acid based active substance combinations against bacteria, mycota and viruses
08/28/2003WO2003051292A3 Novel topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs
08/28/2003WO2003049744B1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
08/28/2003WO2003049698A3 Substituted hydrazones as inhibitors of cyclooxygenase-2
08/28/2003WO2003045364A3 Use of quinazolines to treat t-cell mediated diseases
08/28/2003WO2003045315A3 Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
08/28/2003WO2003041690A3 Three-dimensional suspension printing of dosage forms
08/28/2003WO2003041683A3 Orodispersible tablets containing fexofenadine
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003031449A3 Cross-linked glycopeptide-cephalosporin antibiotics
08/28/2003WO2003031447A3 Pyrimidine derivatives
08/28/2003WO2003029289A3 Fragements of heat shock proteins and their use
08/28/2003WO2003029217A3 Pyridinic sulfonamide derivatives, method of production and use thereof
08/28/2003WO2003028711A3 Use of c-kit inhibitors for the treatment of myeloma
08/28/2003WO2003028641A3 Mch receptor antagonists
08/28/2003WO2003027116A3 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
08/28/2003WO2003024454A3 Topical composition containing brucine and the use for the treatment of damaged mammalian skin
08/28/2003WO2003020202A3 Method for reducing hypertension and heart failure
08/28/2003WO2003017998B1 Platinum complexes and their use in cancer treatment
08/28/2003WO2003017990A3 Ophthalmic composition comprising an ascomycin
08/28/2003WO2003016867A3 Method and quantification assay for determining c-kit/scf/pakt status
08/28/2003WO2003016285A8 Method of preparing 4-(imidazole-1-il)benzenesulphonamide derivatives
08/28/2003WO2003015693A3 Screening and therapeutic methods for promoting wakefulness and sleep
08/28/2003WO2003014153A3 Cellular virus receptors and methods of use.
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2003009699A3 Composition comprising cysteamine for specific use in poultry raising and egg production
08/28/2003WO2003006017A3 Use of certain castanospermine esters in the treatment of influenza virus infections
08/28/2003WO2003004007A3 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
08/28/2003WO2003002559A3 Piperidine compounds for use as orexin receptor antagonist
08/28/2003WO2003002105A3 Use of tyrosine kinase inhibitors for treating bone loss
08/28/2003WO2003002058A3 Bone anabolic compounds and methods of use
08/28/2003WO2002102359A3 Alkylidene pyrazolidinedione derivatives and use for treating diabetes and obesity
08/28/2003WO2002101043A3 Regulation of human ta4 receptor
08/28/2003WO2002100349A3 Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
08/28/2003WO2002100248A3 Compositions and methods relating to glucose metabolism, weight control, and food intake
08/28/2003WO2002083720A3 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
08/28/2003WO2002081508A3 Use of cd25 binding molecules in steroid-resistant patients
08/28/2003WO2002074293A3 Methods for restoring cognitive function following systemic stress
08/28/2003WO2002074235A3 Heterocyclic compounds for therapeutic use
08/28/2003WO2002074048A8 P-glycoproteins and uses thereof
08/28/2003WO2002072534A3 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
08/28/2003WO2002072051A3 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
1 ... 5359 5360 5361 5362 5363 5364 5365 5366 5367 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 ... 7860